title: Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact?
abstract: BACKGROUND
  Regression of breast tumors in response to neoadjuvant chemotherapy is variable. The goal of breast-conservation operation after neoadjuvant chemotherapy is generally to resect any residual tumor with negative margins. There are limited data about the success of achieving negative resection margins in these patients. The purpose of this study was to compare surgical margin involvement of breast-conservation resection specimens from patients treated initially with operation with those from patients receiving neoadjuvant chemotherapy.
  
  
  METHODS
  Between January 2003 and June 2006, 478 breast-conservation operations were performed for invasive breast cancer at our institution. Seventy-six patients received neoadjuvant chemotherapy. Data collected included age, tumor size, nodal status, hormonal receptors and Her-2-neu status, lymphovascular invasion, histologic grade and type, use of guidewire, preoperative chemotherapy regimens, and microscopic evaluation of surgical margins. Univariate analyses and a regression model were used to identify factors associated with margin involvement.
  
  
  RESULTS
  No statistical difference was observed for margin involvement between patients treated with neoadjuvant chemotherapy and those treated initially with operation (21% versus 18%; p = 0.52). Variables associated with positive margins in a logistic regression model were carcinoma type (43% of all lobular carcinomas had positive margins versus 16% in ductal carcinomas; p = 0.002) and hormonal receptor status (margin involvement was present in 20% of tumors that exhibited hormonal receptors versus 10% in negative receptors tumors; p = 0.014).
  
  
  CONCLUSIONS
  Breast conservation after neoadjuvant systemic therapy yields no higher incidence of positive margins than primary surgical treatment. Special consideration should be accorded to lobular carcinoma, because our findings, consistent with previous studies, demonstrate an association with margin involvement.
authors.affiliation: Department of Surgical Oncology, Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, Québec, Canada.
authors.forename: Geneviève
authors.initials: G
authors.lastname: Soucy
authors.forename: Julie
authors.initials: J
authors.lastname: Bélanger
authors.forename: Guy
authors.initials: G
authors.lastname: Leblanc
authors.forename: Lucas
authors.initials: L
authors.lastname: Sideris
authors.forename: Pierre
authors.initials: P
authors.lastname: Drolet
authors.forename: Andrew
authors.initials: A
authors.lastname: Mitchell
authors.forename: Yves E
authors.initials: YE
authors.lastname: Leclerc
authors.forename: Michel P
authors.initials: MP
authors.lastname: Dufresne
authors.forename: Julie
authors.initials: J
authors.lastname: Beaudet
authors.forename: Pierre
authors.initials: P
authors.lastname: Dubé
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D044584:Carcinoma, Ductal / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D018275:Carcinoma, Lobular / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016015:Logistic Models; D015412:Mastectomy, Segmental; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D012189:Retrospective Studies
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; C508053:ERBB2 protein, human